KBC Group NV Acquires 341 Shares of HealthEquity, Inc. (NASDAQ:HQY)

KBC Group NV lifted its stake in HealthEquity, Inc. (NASDAQ:HQY) by 16.1% during the third quarter, HoldingsChannel.com reports. The firm owned 2,463 shares of the company’s stock after purchasing an additional 341 shares during the quarter. KBC Group NV’s holdings in HealthEquity were worth $202,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the stock. Truist Financial Corp increased its stake in HealthEquity by 7.0% during the 2nd quarter. Truist Financial Corp now owns 2,864 shares of the company’s stock valued at $247,000 after purchasing an additional 188 shares in the last quarter. O Shaughnessy Asset Management LLC raised its stake in shares of HealthEquity by 3.9% in the first quarter. O Shaughnessy Asset Management LLC now owns 5,219 shares of the company’s stock worth $426,000 after purchasing an additional 197 shares during the last quarter. Nisa Investment Advisors LLC boosted its position in shares of HealthEquity by 7.5% during the second quarter. Nisa Investment Advisors LLC now owns 2,854 shares of the company’s stock valued at $246,000 after buying an additional 198 shares during the last quarter. Elk River Wealth Management LLC increased its holdings in HealthEquity by 0.3% in the 3rd quarter. Elk River Wealth Management LLC now owns 66,181 shares of the company’s stock worth $5,417,000 after buying an additional 217 shares in the last quarter. Finally, CWM LLC raised its position in HealthEquity by 6.9% in the 2nd quarter. CWM LLC now owns 3,958 shares of the company’s stock worth $341,000 after buying an additional 255 shares during the last quarter. 99.55% of the stock is owned by institutional investors.

Insider Buying and Selling at HealthEquity

In related news, Director Robert W. Selander sold 8,250 shares of the stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the completion of the sale, the director now owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. This represents a 13.10 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Frank Corvino sold 1,247 shares of HealthEquity stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total transaction of $100,084.22. Following the transaction, the director now directly owns 4,823 shares in the company, valued at approximately $387,093.98. This trade represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 10,536 shares of company stock worth $884,517. Insiders own 2.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently commented on HQY shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $92.00 price target on shares of HealthEquity in a research note on Wednesday, September 4th. Barrington Research reaffirmed an “outperform” rating and issued a $105.00 price objective on shares of HealthEquity in a report on Friday, September 20th. BTIG Research boosted their price target on HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, November 14th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of HealthEquity from $102.00 to $103.00 and gave the stock a “buy” rating in a research note on Wednesday, September 4th. Finally, Bank of America boosted their price objective on shares of HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. One research analyst has rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat.com, HealthEquity currently has a consensus rating of “Moderate Buy” and a consensus price target of $107.23.

HealthEquity Stock Performance

Shares of HQY stock opened at $102.96 on Thursday. HealthEquity, Inc. has a 52-week low of $62.10 and a 52-week high of $103.69. The stock’s 50-day moving average price is $86.66 and its 200 day moving average price is $81.57. The company has a quick ratio of 4.10, a current ratio of 4.10 and a debt-to-equity ratio of 0.51. The stock has a market capitalization of $8.99 billion, a PE ratio of 85.80, a price-to-earnings-growth ratio of 1.55 and a beta of 0.52.

HealthEquity (NASDAQ:HQY) last issued its earnings results on Tuesday, September 3rd. The company reported $0.66 EPS for the quarter, topping the consensus estimate of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The company had revenue of $299.93 million for the quarter, compared to analyst estimates of $284.48 million. As a group, equities research analysts forecast that HealthEquity, Inc. will post 2.27 EPS for the current year.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.